0:03
Hello, I'm Jonathan K from UMass Chan Medical School in Worcester, Massachusetts, reporting for RheumNow at ACR Convergence 2026 in Orlando, Florida.
0:13
Today I have Peter Mandel and Gregor Mitt from the University of Vienna School of Medicine who've been presenting a very interesting poster about the
0:26
use of fibroblast activation protein inhibitor coupled to lutetium, a radiolabeled nucleotide — or a nuclide — to target the fibroblasts in rheumatoid arthritis and
0:41
treat active rheumatoid arthritis that's been resistant to other conventional therapies.
0:47
So, Peter, Gregor, tell us a little bit about what you found.
0:52
Yeah, so we had two patients, one with RA and one with PsA who were difficult to treat with a long-standing story of multiple drug failure.
1:02
And we tried to make this approach which has been known in oncology to inject intravenously fibroblast activation protein inhibitor coupled with lutetium.
1:16
And we saw quite good results in a decrease of swollen joint count, tender joint count in both patients.
1:28
So this is very interesting, and Peter, you're targeting tissue-resident fibroblasts.
1:34
It's very difficult to target fibroblasts because unlike circulating T cells or B cells, these are in the synovium.
1:43
How did you come up with this novel idea to take this approach?
1:46
So as Gregor already mentioned, this approach is already used — this compound is already used in oncology — where the idea is of course to bring the lutetium, which is a beta emitter, so it's a systemic radioligand therapy.
2:04
In oncology the idea is that because each tumor has a fibroblast environment or structure around it, you would bring thereby the emitter within the vicinity of the tumor cells.
2:17
In our case, this would be in a way analogous to radiotherapy where we would inject it into a single joint.
2:24
But in our case we give this systemically, and we do see — we saw, in our diagnostic studies — very high uptake of the gallium label.
2:37
Was that the diagnostic FAPI? In the synovial joints of the two patients Gregor mentioned, with difficult-to-treat — one with RA and the other one with PsA.
2:50
So this is a targeted approach, going back to probably 20 or 30 years ago using yttrium injected into the joint as a non-specific way of ablating the inflamed synovium.
3:02
But here you're using a targeted agent to target those fibroblasts that are probably pathogenic in the synovium.
3:11
Yes, as an analogy this is not napalm bombing a forest but, if you may, a targeted intervention of a certain species of plants.
3:20
So this is fantastic. Where do you see this going?
3:23
You've treated two patients — one with so-called difficult-to-treat rheumatoid arthritis, another with multi-drug-experienced psoriatic arthritis.
3:31
What are your current plans for further development?
3:34
So obviously we want to take this forward and treat more patients.
3:38
What we've seen importantly is a decrease in the standardized uptake values on the follow-up PET, if we did that.
3:44
We also did synovial biopsies of these patients before and after the treatment and saw a reduction in the number of FAP-positive expressing fibroblasts, and we did see particularly in the RA patient a steady reduction of disease activity.
3:58
So this is wonderful. This is now a new era of targeted therapies, but using radionuclides instead of antibodies or other protein-derived drugs to treat difficult-to-treat rheumatoid arthritis and other forms of inflammatory arthritis.
4:20
For more information about this and other topics, please go to RheumNow.com.
4:26
I'm Jonathan K with Peter Mandel and Gregor Mitt here at ACR Convergence 2026. See you again soon. Thanks.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.